#MDA2022 – DMD Gene Therapy PF-06939926 Safe at High Dose: Trial
Pfizer's PF-06939926 gene therapy for Duchenne muscular dystrophy (DMD) was well-tolerated and showed hints of efficacy in a Phase 1B trial.
0 Comments
#MDA2022 – DMD Gene Therapy PF-06939926 Safe at High Dose: Trial
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed